Clinical TrialMay 30, 2026, 02:33 PM
Eikon Therapeutics reports positive EIK1001 & EIK1003 clinical trial data
AI Summary
Eikon Therapeutics announced positive updated clinical data for its lead programs, EIK1001 and EIK1003, presented at the 2026 ASCO Annual Meeting. The Phase 2 TeLuRide-005 trial for EIK1001 in NSCLC showed encouraging response rates and a favorable tolerability profile. Additionally, the Phase 1/2 trial for EIK1003, a PARP1 inhibitor, demonstrated antitumor activity as monotherapy and in combination with paclitaxel in advanced solid tumors, with a safety profile consistent with expectations. These results strengthen the case for continued development of both programs.
Key Highlights
- EIK1001 TeLuRide-005 trial in NSCLC showed 63.1% objective response rate (ORR) and 90.8% disease control rate (DCR).
- EIK1001 non-squamous cohort achieved 55.6% ORR and median duration of response >11 months.
- EIK1001 squamous cohort achieved 72.4% ORR and 100% DCR.
- EIK1001 combination therapy was generally well-tolerated, with neutropenia (30.6%) as most common Grade 3+ TRAE.
- EIK1003 monotherapy showed 14.3% ORR overall, 26.7% in PARP-na\u00efve patients.
- EIK1003 in combination with paclitaxel achieved 24.5% ORR in advanced solid tumors.
- EIK1003 combination therapy's most common Grade 3+ TEAE was neutropenia (50%).
Price Impact
More from EIKN